The chemical used in the Trump administration’s new ‘Generation Gold Standard’ bird flu vaccine platform—beta-propiolactone (BPL)—is classified as a ‘Group 2B’ carcinogen by U.S. regulators (meaning the substance is possibly cancer-causing in humans) and as a ‘Group 1B’ carcinogen in Europe (meaning it’s presumed to cause cancer in humans).
A carcinogen is any substance or agent capable of causing cancer by damaging a cell’s DNA and leading to uncontrolled cell growth.
The revelation follows this website’s report that the U.S. National Institute of Allergy and Infectious Diseases (NIAID)—under Dr. Jeffery Taubenberger’s direction—has been funding the creation of chimeric, lab-engineered bird flu viruses in American and foreign laboratories, even as Taubenberger himself is named on a federal patent for the very BPL-utilizing bird flu vaccine platform those experiments are designed to justify.
A May 2025 government press release announced the multi-million dollar BPL platform will be used to generate bird flu pandemic vaccines:
The U.S. Department of Health and Human Services (HHS) and the National Institutes for Health (NIH) today announced the development of the next-generation, universal vaccine platform, Generation Gold Standard, using a beta-propiolactone (BPL)-inactivated, whole-virus platform.
This initiative represents a decisive shift toward transparency, effectiveness, and comprehensive preparedness, funding the NIH’s in-house development of universal influenza and coronavirus vaccines, including candidates BPL-1357 and BPL-24910. These vaccines aim to provide broad-spectrum protection against multiple strains of pandemic-prone viruses like H5N1 avian influenza and coronaviruses including SARS-CoV-2, SARS-CoV-1, and MERS-CoV.
https://open.substack.com/pub/jonfleetwood/p/deadly-cancer-causing-chemical-bpl